Allogene’s cema-cel demonstrates superior MRD negativity in interim Phase 2 ALPHA3 data
Allogene Therapeutics (NASDAQ:ALLO), a pioneer in allogeneic "off-the-shelf" CAR-T cell therapy, announced promising interim futility results today from its randomized Phase 2 ALPHA3 trial.











